Nasdaq determines that transcode therapeutics has regained compliance with continued listing requirements

Transcode shares to remain listed on nasdaq boston , jan. 7, 2025 /prnewswire/ -- transcode therapeutics, inc. (nasdaq: rnaz), the rna oncology company committed to more effectively treating cancer using rna therapeutics, today announced that it has received notice from the nasdaq stock market llc (nasdaq) that the company has regained compliance with listing rules 5550(a)(2) and 5550(b)(1), the exchange's minimum bid price and shareholders' equity rules, respectively. the company has also resolved the violation regarding listing rule 5635 (the "shareholder approval rule") by obtaining shareholder ratification of a july 2024 equity transaction.
NDAQ Ratings Summary
NDAQ Quant Ranking